The information was impossible to ignore. Baseball could not simply dismiss the original Miami New Times report alleging that players had purchased performance-enhancing drugs from Biogenesis, an anti-aging clinic in the Miami area. Not if the sport was serious about cracking down on PED use. Not when the founder of the clinic, Anthony Bosch, was the son of a doctor who allegedly wrote a prescription to Manny Ramirez for female fertility drugs in 2009 — and served as a middle man between the two. No, baseball had to proceed. But why are the sport’s top officials pursuing the case with such intensity? Why are they cutting a deal with Anthony Bosch, whose credibility, if it were a batting average, might be below .200? Those are the biggest questions in the aftermath of baseball reaching agreement with Bosch to testify about his dealings with players, as first reported by ESPN. And the answers rest with commissioner Bud Selig. It is Selig — and Selig alone — who has the power to suspend players under the joint drug agreement even if they do not test positive; a player is subject to disciplinary action for “just cause” by the commissioner if sufficient evidence exists that the player used, purchased or distributed banned drugs. And it is Selig who might be trying to cement his legacy as the commissioner who attacked PEDs; he drew heavy criticism when the use of such drugs erupted under his watch in the late 1990s and early 2000s.